208 related articles for article (PubMed ID: 32687856)
1. Dynamics of cell-free tumour DNA correlate with treatment response of head and neck cancer patients receiving radiochemotherapy.
Hilke FJ; Muyas F; Admard J; Kootz B; Nann D; Welz S; Rieß O; Zips D; Ossowski S; Schroeder C; Clasen K
Radiother Oncol; 2020 Oct; 151():182-189. PubMed ID: 32687856
[TBL] [Abstract][Full Text] [Related]
2. Liquid BIOpsy for MiNimal RESidual DiSease Detection in Head and Neck Squamous Cell Carcinoma (LIONESS)-a personalised circulating tumour DNA analysis in head and neck squamous cell carcinoma.
Flach S; Howarth K; Hackinger S; Pipinikas C; Ellis P; McLay K; Marsico G; Forshew T; Walz C; Reichel CA; Gires O; Canis M; Baumeister P
Br J Cancer; 2022 May; 126(8):1186-1195. PubMed ID: 35132238
[TBL] [Abstract][Full Text] [Related]
3. Next-generation sequencing (NGS) profiling of matched tumor and circulating tumor DNA (ctDNA) in head and neck squamous cell carcinoma (HNSCC).
Economopoulou P; Spathis A; Kotsantis I; Maratou E; Anastasiou M; Moutafi MK; Kirkasiadou M; Pantazopoulos A; Giannakakou M; Edelstein DL; Sloane H; Fredebohm J; Jones FS; Kyriazoglou A; Gavrielatou N; Foukas P; Panayiotides I; Psyrri A
Oral Oncol; 2023 Apr; 139():106358. PubMed ID: 36871349
[TBL] [Abstract][Full Text] [Related]
4. HPV status, cancer stem cell marker expression, hypoxia gene signatures and tumour volume identify good prognosis subgroups in patients with HNSCC after primary radiochemotherapy: A multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG).
Linge A; Lohaus F; Löck S; Nowak A; Gudziol V; Valentini C; von Neubeck C; Jütz M; Tinhofer I; Budach V; Sak A; Stuschke M; Balermpas P; Rödel C; Grosu AL; Abdollahi A; Debus J; Ganswindt U; Belka C; Pigorsch S; Combs SE; Mönnich D; Zips D; Buchholz F; Aust DE; Baretton GB; Thames HD; Dubrovska A; Alsner J; Overgaard J; Krause M; Baumann M;
Radiother Oncol; 2016 Dec; 121(3):364-373. PubMed ID: 27913065
[TBL] [Abstract][Full Text] [Related]
5. Circulating tumour DNA kinetics in recurrent/metastatic head and neck squamous cell cancer patients.
Taylor K; Zou J; Magalhaes M; Oliva M; Spreafico A; Hansen AR; McDade SS; Coyle VM; Lawler M; Elimova E; Bratman SV; Siu LL
Eur J Cancer; 2023 Jul; 188():29-38. PubMed ID: 37182343
[TBL] [Abstract][Full Text] [Related]
6. Tumor-agnostic plasma assay for circulating tumor DNA detects minimal residual disease and predicts outcome in locally advanced squamous cell carcinoma of the head and neck.
Honoré N; van Marcke C; Galot R; Helaers R; Ambroise J; van Maanen A; Mendola A; Dahou H; Marbaix E; Van Eeckhout P; Longton E; Magremanne M; Schmitz S; Limaye N; Machiels JP
Ann Oncol; 2023 Dec; 34(12):1175-1186. PubMed ID: 37879442
[TBL] [Abstract][Full Text] [Related]
7. Individualized circulating tumor DNA monitoring in head and neck squamous cell carcinoma.
Kogo R; Manako T; Iwaya T; Nishizuka S; Hiraki H; Sasaki Y; Idogawa M; Tokino T; Koide A; Komune N; Yasumatsu R; Nakagawa T
Cancer Med; 2022 Nov; 11(21):3960-3968. PubMed ID: 35352507
[TBL] [Abstract][Full Text] [Related]
8. Circulating tumour DNA alterations: emerging biomarker in head and neck squamous cell carcinoma.
Huang X; Duijf PHG; Sriram S; Perera G; Vasani S; Kenny L; Leo P; Punyadeera C
J Biomed Sci; 2023 Aug; 30(1):65. PubMed ID: 37559138
[TBL] [Abstract][Full Text] [Related]
9. Repeat FMISO-PET imaging weakly correlates with hypoxia-associated gene expressions for locally advanced HNSCC treated by primary radiochemotherapy.
Löck S; Linge A; Seidlitz A; Bandurska-Luque A; Nowak A; Gudziol V; Buchholz F; Aust DE; Baretton GB; Zöphel K; Steinbach J; Kotzerke J; Overgaard J; Zips D; Krause M; Baumann M; Troost EGC
Radiother Oncol; 2019 Jun; 135():43-50. PubMed ID: 31015169
[TBL] [Abstract][Full Text] [Related]
10. Cell-Free DNA Kinetics in a Pre-Clinical Model of Head and Neck Cancer.
Muhanna N; Di Grappa MA; Chan HHL; Khan T; Jin CS; Zheng Y; Irish JC; Bratman SV
Sci Rep; 2017 Dec; 7(1):16723. PubMed ID: 29196748
[TBL] [Abstract][Full Text] [Related]
11. Biomarker signatures for primary radiochemotherapy of locally advanced HNSCC - Hypothesis generation on a multicentre cohort of the DKTK-ROG.
Löck S; Linge A; Lohaus F; Ebert N; Gudziol V; Nowak A; Tinhofer I; Kalinauskaite G; Guberina M; Stuschke M; Balermpas P; von der Grün J; Grosu AL; Debus J; Ganswindt U; Belka C; Peeken JC; Combs SE; De-Colle C; Zips D; Baretton GB; Krause M; Baumann M;
Radiother Oncol; 2022 Apr; 169():8-14. PubMed ID: 35182686
[TBL] [Abstract][Full Text] [Related]
12. Circulating tumour DNA alterations as biomarkers for head and neck cancer: a systematic review.
Pall AH; Jakobsen KK; Grønhøj C; von Buchwald C
Acta Oncol; 2020 Jul; 59(7):845-850. PubMed ID: 32223478
[No Abstract] [Full Text] [Related]
13. A comparison between mutational profiles in tumour tissue DNA and circulating tumour DNA in head and neck squamous cell carcinoma - A systematic review.
Huang X; Leo P; Jones L; Duijf PHG; Hartel G; Kenny L; Vasani S; Punyadeera C
Mutat Res Rev Mutat Res; 2024; 793():108477. PubMed ID: 37977279
[TBL] [Abstract][Full Text] [Related]
14. Tumor-Naïve Multimodal Profiling of Circulating Tumor DNA in Head and Neck Squamous Cell Carcinoma.
Burgener JM; Zou J; Zhao Z; Zheng Y; Shen SY; Huang SH; Keshavarzi S; Xu W; Liu FF; Liu G; Waldron JN; Weinreb I; Spreafico A; Siu LL; de Almeida JR; Goldstein DP; Hoffman MM; De Carvalho DD; Bratman SV
Clin Cancer Res; 2021 Aug; 27(15):4230-4244. PubMed ID: 34158359
[TBL] [Abstract][Full Text] [Related]
15. Tumour-agnostic plasma assay for circulating tumour DNA predicts outcome in recurrent and/or metastatic squamous cell carcinoma of the head and neck treated with a PD-1 inhibitor.
Honoré N; van der Elst A; Dietz A; van Marcke C; Helaers R; Mendola A; Dahou H; Marbaix E; Poncin R; Seront E; Schmitz S; Limaye N; Galot R; Machiels JP
Eur J Cancer; 2023 Dec; 195():113372. PubMed ID: 37913682
[TBL] [Abstract][Full Text] [Related]
16. Utility of plasma circulating tumor DNA and tumor DNA profiles in head and neck squamous cell carcinoma.
Chikuie N; Urabe Y; Ueda T; Hamamoto T; Taruya T; Kono T; Yumii K; Takeno S
Sci Rep; 2022 Jun; 12(1):9316. PubMed ID: 35661138
[TBL] [Abstract][Full Text] [Related]
17. Droplet digital PCR for detection and quantification of circulating tumor DNA in plasma of head and neck cancer patients.
van Ginkel JH; Huibers MMH; van Es RJJ; de Bree R; Willems SM
BMC Cancer; 2017 Jun; 17(1):428. PubMed ID: 28629339
[TBL] [Abstract][Full Text] [Related]
18. Mutated
Kampel L; Feldstein S; Tsuriel S; Hannes V; Carmel Neiderman NN; Horowitz G; Warshavsky A; Leider-Trejo L; Hershkovitz D; Muhanna N
Biomolecules; 2023 Sep; 13(9):. PubMed ID: 37759818
[TBL] [Abstract][Full Text] [Related]
19. Blood and saliva-derived ctDNA is a marker of residual disease after treatment and correlates with recurrence in human papillomavirus-associated head and neck cancer.
Ferrier ST; Tsering T; Sadeghi N; Zeitouni A; Burnier JV
Cancer Med; 2023 Aug; 12(15):15777-15787. PubMed ID: 37526056
[TBL] [Abstract][Full Text] [Related]
20. Tumor DNA-methylome derived epigenetic fingerprint identifies HPV-negative head and neck patients at risk for locoregional recurrence after postoperative radiochemotherapy.
Tawk B; Wirkner U; Schwager C; Rein K; Zaoui K; Federspil PA; Adeberg S; Linge A; Ganswindt U; Hess J; Unger K; Tinhofer I; Budach V; Lohaus F; Krause M; Guberina M; Stuschke M; Balermpas P; Rödel C; Grosu AL; Schäfer H; Zips D; Combs SE; Pigorsch S; Zitzelsberger H; Baumeister P; Kirchner T; Bewerunge-Hudler M; Weichert W; Hess J; Herpel E; Belka C; Baumann M; Debus J; Abdollahi A;
Int J Cancer; 2022 Feb; 150(4):603-616. PubMed ID: 34648658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
